Details of the Drug Combination

General Information of Drug Combination (ID: DC5RZV3)

Drug Combination Name
Ospemifene RG6046
Indication
Disease Entry Status REF
Lymphoid neoplasm Investigative [1]
Component Drugs Ospemifene   DMC4GEI RG6046   DMGYWIK
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: Mak
Zero Interaction Potency (ZIP) Score: 11.023
Bliss Independence Score: 10.482
Loewe Additivity Score: 5.901
LHighest Single Agent (HSA) Score: 12.024

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ospemifene
Disease Entry ICD 11 Status REF
Dyspareunia GA12 Approved [2]
Postmenopausal vaginal atrophy GA30.2 Phase 3 [2]
Ospemifene Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Ospemifene Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [5]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [5]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Ospemifene Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Expression [6]
Trefoil factor 1 (TFF1) OTCYQH4F TFF1_HUMAN Decreases Expression [6]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of RG6046
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Investigative [3]
RG6046 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7349).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of Shionogi (2011).
5 Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
6 Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016 Jul;23(7):719-30. doi: 10.1097/GME.0000000000000624.